Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vijaya Korrapati (NPI 1033186713)

Field	Value
Entity Type	Individual
Organization	Vijaya Korrapati
Address	222 E Medical Ln Ste 400
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 2, 2006

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This profile is consistent with an infusion-focused Hematology & Oncology practice: the three top Medicare revenue drivers are J9271 ($944K, 28.3%), J9299 ($398.4K, 12.0%), and J9144 ($304.6K, 9.1%), and the provider’s total Medicare revenue is $3.4M. Those leading codes are high-cost oncology therapeutics (pembrolizumab, nivolumab, daratumumab), indicating routine administration of immune checkpoint inhibitors and monoclonal antibody therapies in-office or in an infusion suite. The precomputed top-3 share of revenue is 49.4%, underscoring how much of the practice’s Medicare revenue is oncology drug-driven.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 49.4% of the provider’s Medicare revenue, signaling material dependence on a small set of immuno-oncology and monoclonal antibody agents for overall topline performance. That concentration means changes in utilization or reimbursement for these specific drugs could meaningfully affect the practice’s Medicare revenue mix.

This provider is effectively single-payer in active billing: Medicare revenue is $3.4M while Medicaid billing is recorded as none, so the practice’s publicly visible reimbursement exposure is concentrated in Medicare. As a result, payer-policy shifts at Medicare (coverage, pricing, or site-of-care rules) are likely more impactful to the business than in-state Medicaid changes, since no Medicaid revenue is on file.

Competitive standing is mixed across agents: for some supportive and chemotherapy-related codes the provider ranks well above peers (examples include J2506 at rank #19 of 586, 97th percentile described as "notably above typical", J9035 at rank #41 of 1852, 98th percentile "notably above typical", and 96413 at rank #461 of 7514, 94th percentile "notably above typical"). These high percentiles suggest the practice is a relatively large user of supportive agents (pegfilgrastim) and infusion chemotherapy administration compared with national peers.

By contrast, for several high-cost immunotherapies the provider’s national standing is more typical: J9271 ranks #260 of 1841 (86th percentile, characterized as "typical, unremarkable volume"), J9299 ranks #213 of 505 (58th percentile, "typical, unremarkable volume"), and J9144 ranks #290 of 615 (52th percentile, "typical, unremarkable volume"). This pattern indicates solid clinical volume for these agents but not dominant national leadership in their use.

The practice also shows measurable use of advanced diagnostic imaging linked to oncology care: A9595 generated $192.7K (5.8% of Medicare revenue) and 78815 generated $146.8K (4.4% of Medicare revenue), with both codes ranked in middle-to-upper percentiles (A9595 at the 76th percentile, 78815 at the 85th percentile, each described as "typical, unremarkable volume"). This supports an operating model that pairs systemic therapy with PET/CT and targeted radiotracers for diagnostic staging or treatment planning.

Operational throughput is evident in routine support services and low-per-claim items: examples include J1439 with 44.3K claims ($44.3K revenue), 36415 with 1.6K claims ($11.3K revenue, 99th percentile), and multiple laboratory codes (80048 at 914 claims, 97th percentile). High claim counts for low-dollar items alongside concentrated high-dollar drug revenue are consistent with a high-volume infusion clinic that also bills frequently for specimen collection and lab monitoring.

The provider’s enrollment tenure is long-standing: the NPI was enumerated on 2006-03-02 (~20 years ago), indicating roughly two decades of presence in the Medicare billing landscape and suggesting established referral relationships and practice infrastructure supporting ongoing oncology treatment volumes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

89 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	23,600	$40	$944K
J9299	Injection, nivolumab, 1 mg	16,600	$20	$398.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,460	$40	$304.6K
J0897	Injection, denosumab, 1 mg	13,200	$20	$250.8K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	420	$460	$192.7K
J9022	Injection, atezolizumab, 10 mg	2,990	$60	$191.2K
J9173	Injection, durvalumab, 10 mg	2,800	$60	$173.8K
J9312	Injection, rituximab, 10 mg	2,330	$60	$149.4K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	210	$710	$146.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,160	$80	$93.1K

Showing 1–10 of 89

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 89 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Vijaya Korrapati — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

89 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	30	19,700	$40	$832K
J9299	6	10	15,760	$20	$432K
J9144	6	10	8,460	$40	$349.4K
J9173	4	10	3,050	$60	$275.9K
J9022	4	10	3,550	$60	$239.1K
J9312	12	20	2,340	$60	$193.7K
A9595	5	10	410	$460	$175.9K
J0897	27	250	2,400	$20	$91.2K
J2506	1	10	740	$80	$55.9K
J1439	15	30	42,750	$1	$42.3K

Showing 1–10 of 89

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vijaya Korrapati, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
Lexington Health Inc	SC	Urgent Care Clinic/Center	$0	$8.7M
Lexington Health Inc	SC	Pediatric Adolescent Medicine Physician	$0	$5.7M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0
Lexington Health Inc	SC	Family Medicine Physician	$0	$4M
Lexington Health Inc	SC	Obstetrics & Gynecology Physician	$0	$3.5M
Perrie Ryan	SC	Hematology & Oncology Physician	$3.3M	$0

Nearby Providers

Other providers in the same ZIP code as Vijaya Korrapati, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Lexington Treatment Specialists LLC	SC	Methadone Clinic	$76.7K	$3.6M
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Asheesh Lal	SC	Hematology & Oncology Physician	$3.2M	$0
James Wells	SC	Hematology & Oncology Physician	$3.2M	$0

Vijaya Korrapati — Billing Profile & Reimbursement Data

Sign up for Vijaya Korrapati — Billing Profile & Reimbursement Data policy alerts

Vijaya Korrapati — Billing Profile & Reimbursement Data

Sign up for Vijaya Korrapati — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References